Please login to the form below

Not currently logged in
Email:
Password:

Verona Pharma appoints Dr Sven Jan-Anders Karlsson as CEO

He takes over from the UK biotech company's co-founder Michael Walker

Verona Pharma has appointed Dr Sven Jan-Anders Karlsson to be the respiratory-focused biotech's new CEO.

He replaces Michael Walker, one of the UK-based company's co-founders, who is stepping down from his position but will remain as a senior scientific advisor to the board.

Dr Karlsson was most recently a director of S*BIO, a Singapore- and US-based biotech focused on developing small molecule anti-cancer drugs.

Prior to his time at S*BIO, Dr Karlsson was executive VP of pharma global research at Bayer Healthcare and before that he held senior leadership positions at Rhone-Poulenc Rorer (now Sanofi) and Astra (now AstraZeneca).

“We have taken time to identify and recruit the right person to take over from Michael after he had notified the Board of his intention to step down,” said company chair Professor Clive Page.

“We believe Jan-Anders' experience in the pharmaceutical and biotechnology sector will be invaluable to Verona Pharma as we move our clinical programmes forward, and continue to grow and expand the company. We very much look forward to working with him.”

2nd May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics